Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Dr Reddy's Laboratories reported a 1.4% increase in consolidated net profit to ₹1,409 crore for Q1FY26, compared to ₹1,392 ...

Dr Reddy’s kicks off India’s big pharma earnings season with a narrow profit miss. The pharmaceutical company reported a ...

If approved, Beyfortus would become the first and only single-dose, passive immunisation for a broad infant population, including those born healthy, at term or preterm, or with specific health ...

MORRISTOWN, NJ, USA I July 22, 2025 I The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Q1FY26 revenues at ?12.7 billion, YoY growth of 142% and flat QoQ growth. This includes revenues from the acquired NRT business.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi, with a price target of €100.00. The company’s shares closed yesterday at $95.42. Take advantage of ...

Following a recommendation from a panel of CDC advisors, HHS Secretary Robert F. Kennedy Jr. on Wednesday ordered that the ...